PMID- 33836479
OWN - NLM
STAT- MEDLINE
DCOM- 20210824
LR  - 20210824
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 105
DP  - 2021 Jun
TI  - 25-Hydroxy vitamin D deficiency predicts inferior prognosis in Hodgkin lymphoma.
PG  - 106580
LID - S0145-2126(21)00081-3 [pii]
LID - 10.1016/j.leukres.2021.106580 [doi]
AB  - The study investigated serum 25-Hydroxy vitamin D (25-(OH)D) deficiency and its 
      prognostic values of patients newly diagnosed Hodgkin lymphoma (HL). With 
      seventy-seven patients enrolled, the median level of 25-(OH)D was 44.5 nmol/L 
      (range, 15.5-100.9 nmol/L) and 16 (20.8 %) of them were considered as 25-(OH)D 
      deficiency. With a median follow-up of 28 months (range, 4-56 months), the 2-year 
      progression-free survival (PFS) and overall survival (OS) rate were 75.3 %+/-5.5 % 
      and 94.7 %+/-3.0 %, respectively. Patients with deficient 25-(OH)D level had 
      inferior PFS (P<0.001) as well as OS (P<0.001). In multivariate Cox analysis, 
      25-(OH)D deficiency was observed as an independent prognostic factor for both PFS 
      (hazard ratio (HR) 3.323, 95 % CI 1.527-7.229, P = 0.002) and OS (HR 5.819, 95 % 
      CI 1.322-25.622, P = 0.020). Receiver-operator characteristic (ROC) curve showed 
      International Prognostic Score (IPS) plus 25-(OH)D deficiency (IPS-D) predicted 
      more accurately than IPS in PFS (AUC: 0.735 (95 % CI 0.622-0.829) vs. 0.701 (95 % 
      CI 0.586-0.800), P = 0.033) and OS (AUC: 0.864 (95 % CI 0.767-0.932) vs. 0.825 
      (95 % CI 0.722-0.902), P = 0.028). All these findings suggest that serum 25-(OH)D 
      level may be an adjunctive indicator to predict prognosis in HL patient.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Qin, Jia-Qi
AU  - Qin JQ
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
FAU - Yin, Hua
AU  - Yin H
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
FAU - Wu, Jia-Zhu
AU  - Wu JZ
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
FAU - Chen, Rui-Ze
AU  - Chen RZ
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
FAU - Xia, Yi
AU  - Xia Y
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
FAU - Zhu, Hua-Yuan
AU  - Zhu HY
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
FAU - Fan, Lei
AU  - Fan L
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
FAU - Li, Jian-Yong
AU  - Li JY
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
FAU - Liang, Jin-Hua
AU  - Liang JH
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China. 
      Electronic address: 1151525490@qq.com.
FAU - Xu, Wei
AU  - Xu W
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of 
      Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China. 
      Electronic address: xuwei10000@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210329
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Biomarkers, Tumor)
RN  - 1406-16-2 (Vitamin D)
RN  - A288AR3C9H (25-hydroxyvitamin D)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers, Tumor/*blood
MH  - Child
MH  - Female
MH  - Hodgkin Disease/*blood/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vitamin D/analogs & derivatives/blood
MH  - Vitamin D Deficiency/*blood
MH  - Young Adult
OTO - NOTNLM
OT  - 25-Hydroxy vitamin D
OT  - Hodgkin lymphoma
OT  - Overall survival
OT  - Prognosis
OT  - Progression-free survival
EDAT- 2021/04/10 06:00
MHDA- 2021/08/25 06:00
CRDT- 2021/04/09 20:20
PHST- 2021/01/19 00:00 [received]
PHST- 2021/02/19 00:00 [revised]
PHST- 2021/03/09 00:00 [accepted]
PHST- 2021/04/10 06:00 [pubmed]
PHST- 2021/08/25 06:00 [medline]
PHST- 2021/04/09 20:20 [entrez]
AID - S0145-2126(21)00081-3 [pii]
AID - 10.1016/j.leukres.2021.106580 [doi]
PST - ppublish
SO  - Leuk Res. 2021 Jun;105:106580. doi: 10.1016/j.leukres.2021.106580. Epub 2021 Mar 
      29.